BioSpace News Archive

Ocular Therapeutix™, Inc. announced the pricing of an underwritten public offering of 7,180,000 shares of its common stock at a public offering price of $9.75 per share for gross proceeds of approximately $70 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

First demonstration ofantiviral effectof nitric oxide-based medicine against SARS-CoV-2 in an in vitro model thatmimicsthe human airway epithelium

Actinium Pharmaceuticals, Inc. announced the launch of its new research and development lab facility in New York City.

The College of American Pathologists, the world’s largest organization for the doctors who diagnose and study disease, recognized several of its members for their dedication to and advancement of pathology and laboratory medicine.

NeuroRx, Inc., a clinical-stage pharmaceutical company developing small molecules for unmet medical needs, announced that Chairman and CEO Jonathan C.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced unaudited preliminary revenue results for the third quarter ended September 30, 2020 . The Company expects to report third quarter revenue in th

Acceptance marks critical milestone in Biohaven’s efforts to develop NURTEC ODT as a unique dual therapy for both the preventive and acute treatment of migraine NURTEC ODT 75 mg has been shown in placebo-controlled trials to return patients to normal functioning within 60 minutes when used in the acute treatment of migraine and has also been shown to reduce monthly migraine days at the same 75 mg dose administered every other day for preventive treatment

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020. The details of the poster presentations include: “ Sulbactam- durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter

According to the report, the global urodynamics equipment and disposables market was valued at US$ 196.5 Mn in 2019 and is projected to reach US$ 386 Mn by 2030, expanding at a CAGR of ~6% from 2020 to 2030.

The global pharmaceutical lipids market is foreseen to grow at significant rate during the forecast period of 2020 to 2030.